NAFLD和NAFLD相关的HCC:新兴的治疗方法和临床试验
Tripti Khare1,2, Karina Liu3, Lindiwe Oslee Chilambe4
1Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri, Columbia, MO 65212, USA.
与代谢相关的脂肪肝疾病 (MAFLD) 是常见的,并与肝癌有关. 最近的试验显示了像resmetirom这样的治疗方法的前景,Rezdiffra成为FDA批准的MAFLD/NASH的第一个药物.
科学领域:
- 肝病学和胃肠道学
- 临床试验和治疗方法
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 非酒精性脂肪性肝病 (NAFLD),现在是代谢相关脂肪性肝病 (MAFLD),是全球最普遍的肝病.
- MAFLD越来越多地与肝细胞癌 (HCC) 相关,需要改进监测和治疗策略.
- 目前在MAFLD患者中对HCC的监测仍然低于最佳.
研究的目的:
- 审查最近 (5-7年) 对MAFLD,非酒精性脂肪肝炎 (NASH) 和HCC的有前途的治疗方法和临床试验.
- 根据干预类型对正在进行和已完成的试验进行分类.
- 突出MAFLD/NASH治疗选择和诊断生物标志物的进展.
主要方法:
- 对专注于MAFLD,NASH和HCC干预的临床试验的系统审查.
- 根据治疗方法对试验进行分类 (例如药物学,手术,饮食).
- 分析已完成的试验,以获得确的结果,以及正在进行的试验,以获得新出现的数据.
主要成果:
- 磨碎的奇亚种子 (NCT03942822) 和减肥手术 (RYGB/SG,NCT03524365) 显示对NAFLD/NASH有好处.
- 血液生物标志物在预测NASH和纤维化方面表现出准确性 (NCT04677101).
- 在NCT03900429中的Resmetirom (MGL-3196) 显著改善了NASH患者的纤维化和脂质概况,导致Rezdiffra获得FDA批准.
结论:
- 雷兹迪夫拉 (resmetirom) 是FDA批准用于MAFLD/NASH的第一个药物,标志着显著的治疗进展.
- 虽然许多试验正在进行中,但早期结果表明药理和手术干预的进展.
- 改进的诊断工具和向治疗对于管理MAFLD和相关HCC的日益增加的负担至关重要.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chronic Pancreatitis II: Collaborative Care
Assessment:
